文献速递肾癌与肾肿瘤

活检确诊的嗜酸性肾肿瘤主动监测:生长动态与肾功能影响

Active Surveillance of Biopsy-Confirmed Oncocytic Renal Tumors: Growth Dynamics and Impact on Renal Function.
PubMed 文献 · J Urol · 2025-08-08

本研究回顾性分析229例活检确诊的嗜酸性肾肿瘤(222例嗜酸细胞瘤,23例嫌色细胞肾细胞癌)接受主动监测的患者,发现肿瘤生长缓慢,预测生长率分别为0.21 cm/y和0.31 cm/y,干预率低,肾功能保持稳定,中位随访5.7年无转移或肾癌相关死亡。

要点

  • 活检确诊的嗜酸性肾肿瘤主动监测下生长缓慢,干预率低。
  • 基线肿瘤较大与生长更快相关,年龄与生长率呈负相关。
  • 肿瘤大小与肾功能下降无显著关联,随访期间无转移或肾癌死亡。

核心结论

  • 活检确诊的嗜酸性肾肿瘤主动监测显示生长缓慢、干预率低、肾功能保持良好且疾病特异性生存极佳。

研究设计与样本

  • 单中心回顾性研究纳入2003-2021年活检确诊为嗜酸细胞瘤或嫌色细胞肾细胞癌并接受主动监测的患者229例(245个病灶)。

主要发现

  • 预测生长率嗜酸细胞瘤为0.21 cm/y,嫌色细胞肾细胞癌为0.31 cm/y。
  • 基线肿瘤较大与生长更快相关(P = .04),年龄与生长率呈负相关(P < .01)。
  • 嫌色细胞肾细胞癌组干预更常见(35% vs 13%)。
  • 活检与手术病理一致率嗜酸细胞瘤为80%,嫌色细胞肾细胞癌为86%。
  • 肿瘤大小与肾功能下降(P = .3)或水平(P = .6)无显著关联,中位随访5.7年(IQR: 3.0, 8.7)无转移或肾癌相关死亡。

关键数值与推荐

  • 活检与手术病理一致率:嗜酸细胞瘤80%,嫌色细胞肾细胞癌86%。
  • 干预率:嫌色细胞肾细胞癌组35%,嗜酸细胞瘤组13%。

临床怎么用

  • 对于活检确诊的嗜酸性肾肿瘤,主动监测是有效的管理策略,可依据组织学类型指导监测强度。

局限性

  • 单中心回顾性设计可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Oncocytic neoplasms account for up to 15% of small renal masses. Active surveillance (AS) is increasingly adopted for these lesions; however, knowledge gaps remain regarding their growth kinetics, concordance with renal tumor biopsy, and impact on renal function. This study reviews these factors in the largest cohort of biopsy-confirmed oncocytic neoplasms managed with AS. MATERIALS AND METHODS: This single-center, retrospective study included patients with biopsy-confirmed oncocytoma or chromophobe renal cell carcinoma (chRCC) on AS (2003-2021). Tumor growth rates and change in renal function (estimated glomerular filtration rate) were analyzed using linear mixed models, while development of chronic kidney disease was assessed using Cox proportional hazards model. Biopsy-to-surgical pathology concordance and triggers for intervention were examined. RESULTS: Among 229 patients (245 lesions; 222 oncocytomas, 23 chRCC), the median time between first and last imaging was 4.7 and 2.5 years, respectively. Predicted growth rates were 0.21 cm/y (oncocytoma) and 0.31 cm/y (chRCC). Larger baseline tumor size correlated with faster growth (P = .04), while age inversely correlated with growth rate (P < .01). Intervention was more common in the chRCC cohort (35% vs 13%). Biopsy-to-surgical pathology concordance rates were 80% for oncocytoma and 86% for chRCC. No significant association was found between tumor size and renal function decline (P = .3) or level (P = .6). There were no events of metastases or kidney cancer-related deaths over a median follow-up of 5.7 years (IQR: 3.0, 8.7). CONCLUSIONS: Oncocytic lesions on AS demonstrate slow growth, low intervention rate, preservation of renal function, and excellent disease-specific survival. Although biopsy limitations exist, histology-guided AS provides effective management.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Raveendran L, Martin LJ, Cheung DC, et al. Active Surveillance of Biopsy-Confirmed Oncocytic Renal Tumors: Growth Dynamics and Impact on Renal Function. J Urol. 2025. PMID: 40779654. doi:10.1097/JU.0000000000004717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。